Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was up +0.01% ($0.01) to $100.76 and showed a volume of 0.58 mln shares. It has ranged in price between $98.77-$102.16 after having started the session at $101.49 as compared to the previous trading day’s close of $100.75. The GAP was therefore 0.73%. Over the 52-week time span, the stock notched a high price of $153.99 and its minimum price was $48.79. The firm’s stock has a market capitalization of $10.24 bln.
The analysts offering 12 month price targets for Alnylam Pharmaceuticals, Inc. have a median target of $156.5, with a high estimate of $207 and a low estimate of $86. The median estimate represents a 55.32% increase from the last price.
According to Zacks brokerage recommendations, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s Buy count is 1 and Strong Buy is 11 while the number of analysts recommending Sell and Strong Sell are 0 and 3, respectively. Also, the Hold rating count is 1, as of 13 Apr 2018. The analyst recommendations from a month ago are 1 Buy, 10 Strong Buy, 0 Sell, 1 Hold and 2. Strong Sell. Investors might also notice that two months ago the Buy recommendations (1) outnumbered Sell recommendations (0). The count of Hold ratings in that period was 1. Chicago-based equity research firm Zacks Investment Research has assigned this stock ABR (Average Brokerage Recommendation) of 1.69, indicating analysts in general look favorably on the company’s future prospects.
Now, the FactSet Research estimate calls for earnings of US$-1.5. A month ago, analyst EPS consensus estimated earnings of US$-1.43 per share. They were forecasting US$-1.45 per share three months ago. The consensus earnings estimates for the company have stabilized at US$-1.77 per share. A month ago, they told us to expect earnings of US$-1.76 per share while three months ago their EPS consensus estimate was US$-1.54.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) tumbled -20.69% year-to-date. The shares have slowed down in recent weeks, with their price down about -21.31% in the past three months. ALNY rose 5.97%, plunged -28.96% and sank -19.3% in the week, one month and six months, respectively. The most recent short interest data show 5.42% of the company’s stock are short sold. It would take about 4.54 days to cover all short positions. In terms of volatility, it has a beta coefficient of 2.68 and technical analysis volatility indicator called Average True Range or ATR around 6.71.
Alnylam Pharmaceuticals, Inc. (ALNY) closed -9.89% below its 200-day moving average and is -18.03% below another chart threshold, its 50-day moving average. The stock stands nearly -34.57% off versus the 52-week high and 106.52% away from the 52-week low. The number of shares currently owned by investors are 101.6 mln.